导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.76% | 2627/4765 |
| 近一周 | -1.81% | 2891/5455 |
| 近一月 | -3.38% | 2442/5411 |
| 近一季 | -6.24% | 2336/5221 |
| 近半年 | -1.68% | 1852/4910 |
| 近一年 | 2.02% | 2364/4390 |
| 近两年 | 44.88% | 1674/2953 |
| 近三年 | 28.03% | 1168/2252 |
| 成立以来 | 93.15% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.71% 3369/4961 |
12.48% 2171/5312 |
- - |
- - |
| 2025 | 19.48% 2214/4813 |
-1.14% 2591/3635 |
2.01% 1945/4076 |
18.32% 2315/4524 |
0.13% 2192/4813 |
| 2024 | 15.49% 922/3463 |
2.72% 722/2808 |
-1.21% 986/3014 |
16.06% 1550/3129 |
-1.93% 1891/3463 |
| 2023 | -7.75% 947/2656 |
4.32% 986/2280 |
-3.67% 858/2385 |
-2.30% 657/2515 |
-6.04% 1608/2655 |
| 2022 | -18.07% 659/2207 |
-13.69% 816/1919 |
6.95% 569/2016 |
-13.00% 816/2113 |
2.01% 1063/2208 |
| 2021 | 2.52% 630/1822 |
-1.32% 469/1255 |
5.71% 795/1330 |
-3.60% 648/1466 |
1.96% 739/1822 |
| 2020 | 36.03% 405/1250 |
-9.43% 676/1028 |
13.40% 622/1067 |
16.15% 165/1164 |
14.03% 306/1184 |
| 2019 | 35.88% 366/1092 |
26.84% 374/754 |
0.06% 202/804 |
0.41% 518/850 |
6.63% 579/918 |
| 2018 | -21.46% 214/834 |
- - |
- - |
- - |
-11.50% 305/691 |
| 2017 | 24.03% 127/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.58% 265/605 |
- - |
- - |
- - |
- - |
| 2015 | 6.35% 197/575 |
- - |
- - |
- - |
- - |
| 2014 | 50.09% 85/237 |
- - |
- - |
- - |
- - |
| 2013 | -6.00% 106/186 |
- - |
- - |
- - |
- - |
| 2012 | 8.43% 54/140 |
- - |
- - |
- - |
- - |
| 2011 | -23.70% 64/102 |
- - |
- - |
- - |
- - |
| 2010 | -12.28% 32/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 建信沪深300指数(LOF) VS. 长安沪深300非周期A(740101) |